We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $2B
1-Year Est. Return 147.21%
This Fund
S&P 500
This Quarter Est. Return
-23.09%
1 Year Est. Return
+147.21%
3 Year Est. Return
+369.71%
5 Year Est. Return
+164.99%
10 Year Est. Return
+6,568.53%
AUM
$87.1M
AUM Growth
-$26.1M
Cap. Flow
+$5.24M
Cap. Flow %
6.02%
Top 10 Hldgs %
66.86%
Holding
37
New
6
Increased
12
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
FMI
Foundation Medicine, Inc.
FMI
+$3.54M
2
EDIT icon
Editas Medicine
EDIT
+$2.25M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.2M
4
KITE
Kite Pharma, Inc.
KITE
+$2.18M
5
EPZM
Epizyme, Inc
EPZM
+$2.15M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$5.76M
2
GHDX
Genomic Health, Inc.
GHDX
+$3.02M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.41M
4
NVTA
Invitae Corporation
NVTA
+$2.05M
5
BPMC
Blueprint Medicines
BPMC
+$1.58M

Sector Composition

Rank Sector Weight
1 Healthcare 96.59%
2 Miscellaneous 2.96%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$6.83M 7.85%
250,000
-1,500
-0.6% -$31.4K
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$6.61M 7.58%
545,000
+212,500
+64% +$2.15M
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
$6.09M 6.99%
335,000
+220,000
+191% +$3.54M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$6.06M 6.95%
189,000
+45,989
+32% +$1.62M
AGIO icon
5
Agios Pharmaceuticals
AGIO
$2.01B
$6.01M 6.9%
148,000
+51,500
+53% +$2.2M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$5.8M 6.66%
321,300
-91,200
-22% -$1.58M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$32.9B
$5.65M 6.48%
90,000
+30,000
+50% +$1.99M
BLUE
8
DELISTED
bluebird bio
BLUE
$5.1M 5.85%
9,264
+1,544
+20% +$948K
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.09M 5.84%
475,350
+71,478
+18% +$650K
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.02M 5.76%
170,000
+25,000
+17% +$789K
CTMX icon
11
CytomX Therapeutics
CTMX
$614M
$4.14M 4.75%
321,023
– –
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
$3.44M 3.95%
75,000
+45,000
+150% +$2.18M
VYGR icon
13
Voyager Therapeutics
VYGR
$187M
$2.96M 3.4%
339,362
+102,500
+43% +$1.16M
EDIT icon
14
Editas Medicine
EDIT
$418M
$2.95M 3.39%
+85,470
New +$2.25M
DXCM icon
15
DexCom
DXCM
$33.2B
$2.72M 3.12%
160,000
+92,000
+135% +$1.54M
XBI icon
16
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
$2.58M 2.96%
+50,000
New +$2.6M
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.72M 1.97%
+63,000
New +$1.38M
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.67M 1.91%
105,000
+40,000
+62% +$711K
GHDX
19
DELISTED
Genomic Health, Inc.
GHDX
$1.36M 1.56%
55,000
-110,000
-67% -$3.02M
BMY icon
20
Bristol-Myers Squibb
BMY
$128B
$1.34M 1.54%
21,000
-11,164
-35% -$704K
BIIB icon
21
Biogen
BIIB
$32.4B
$1.3M 1.49%
5,000
-4,000
-44% -$1.06M
ONC
22
BeOne Medicines Ltd
ONC
$40B
$953K 1.09%
+32,500
New +$921K
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
$745K 0.86%
+110,000
New +$906K
EXAS
24
DELISTED
Exact Sciences
EXAS
$404K 0.46%
+60,000
New +$384K
MDSO
25
DELISTED
Medidata Solutions, Inc.
MDSO
$387K 0.44%
10,000
– –
1
2

Similar funds

KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.99B AUM 86.33% 1-Year Est. Return
SB
Strategic Blueprint Atlanta, Georgia $2B AUM 27.02% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
FOF
Fenelon Opportunity Fund Dallas, Texas $2.01B AUM

Casdin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Casdin Capital held 37 positions worth $87.1M, down 23% from $113M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Casdin Capital deployed $5.24M of net new capital in Q1 2016, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Editas Medicine: 85,470 shares worth $2.95M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Genomic Health, Inc., an estimated $3.02M trimmed.

  • Casdin Capital's largest Q1 2016 buy was Editas Medicine: 85,470 shares worth $2.95M.
  • Casdin Capital added most to Foundation Medicine, Inc. in Q1 2016, an estimated $3.54M increase.
  • Casdin Capital's biggest Q1 2016 reduction was Genomic Health, Inc., cutting an estimated $3.02M.
  • Casdin Capital fully exited Illumina in Q1 2016, selling an estimated $5.76M.
  • Casdin Capital's ten largest holdings make up 67% of its $87.1M portfolio in Q1 2016.
  • Casdin Capital opened 6 new positions and closed 11 in Q1 2016.
  • Casdin Capital's portfolio value fell 23% quarter-over-quarter to $87.1M.

Based on Casdin Capital's 13F filing for Q1 2016, filed 9 May 2016.